HLN — Haleon plc
Is HLN overbought or oversold? Here is the current MarketMoodz read.
Haleon plc (HLN) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $9.20. The rating moved from Oversold to Neutral on November 13, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$9.20
- Last changeMoved from Oversold to Neutral on November 13, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
AI analysis
Haleon benefits from a resilient consumer-health product mix, strong brand franchises and recent share‑buyback activity that support cash flow and shareholder returns. Near-term support is likely from defensive sector flows and stable demand, while growth depends on successful product execution and margin management. Key watch items include competitive pressure, FX exposure and execution of efficiency initiatives that will determine upside over the next month.
Key factors
- Large, defensive consumer-health portfolio with trusted brands and recurring demand supporting stable cash flow
- Recent 6-K disclosure of transactions in own shares indicates shareholder returns and management confidence
- Sector flows favoring large-cap pharma/defensive exposures amid risk-on-with-caution market tone
- Stable margin profile and cost-savings potential from post-spin operational efficiencies
- Limited near-term macro/geopolitical volatility in the last trading window enabling focus on earnings and fundamentals
- Diversified geographic exposure that reduces single-market dependency
Risks
- Intense competition from generics and private-label store brands that can pressure market share and pricing
- Foreign-exchange volatility could weigh on reported revenues and margins given substantial international exposure
- Slower-than-expected organic growth in key categories or failure of new product launches
- Regulatory, labeling or litigation risks inherent to consumer healthcare products
- Execution risk on cost-savings initiatives and integration of any acquisitive activity
- Macro weakness in discretionary markets or changes in payer/retailer dynamics that reduce retail volumes
See today's live rating, score and targets
Members see the live hourly rating for HLN — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.